Sharekhan

Supriya Lifescience Ltd

Fri 20/02/2026,15:44:59 NSE: SUPRIYA

₹ 677.95 -6.70 (-0.98%)
BUY NOW Buy Supriya Lifescience Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Supriya Lifescience Ltd

Fri 20/02/2026,16:1:0

Supriya Lifescience Ltd

Fri 20/02/2026,15:44:59 | NSE : SUPRIYA

₹ 677.95-6.70 (-0.98%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 684.30

Previous Close

₹ 684.65

Volume

51078

Mkt Cap ( Rs. Cr)

₹5456.33

High

₹ 684.30

Low

₹ 673.00

52 Week High

₹ 842.00

52 Week Low

₹ 556.15

Book Value Per Share

₹ 134.41

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Supriya Lifescience Ltd

Your Vote -

Buy

65.91%

Hold

5.68%

Sell

28.41%

65.91%

88 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

677.95

25

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

25

Option Chain

Analyzes market sentiment, predicts Supriya Lifescience Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Feb 2026, 10:48AM Supriya Lifescience Limited has informed the Exchange about Transcript

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    17 Feb 2026, 10:52AM Transcript of the Earnings Call for the Unaudited Financial Results for quarter and nine months ended December 31, 2025, is enclosed herewith.\r\nKind

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Feb 2026, 4:24PM Supriya Lifescience Limited has informed the Exchange about Link of Recording

  • Supriya Lifescience - Copy of Newspaper Publication

    10 Feb 2026, 1:11PM Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication of Unaudited Financial Results of the Company for quarter an

  • Supriya Lifescience - Press Release

    10 Feb 2026, 1:05PM Supriya Lifescience Limited has informed the Exchange regarding a press release dated February 10, 2026, titled ""Press Release- Unaudited Financial R

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    10 Feb 2026, 4:25PM Audio Recording of the Earnings Call for Unaudited Financial Results of quarter and nine months ended December 31, 2025 is enclosed herewith.

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    10 Feb 2026, 1:06PM Press Release for Unaudited Financial Results for quarter and nine months ended December 31, 2025 is enclosed.

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Investor Presentation

    9 Feb 2026, 7:59PM Investor Presentation for Results Earnings Call for Quarter and Nine Months ended on December 31, 2025 is enclosed herewith.\r\n\r\nKindly take the sa

  • Supriya Lifescience - Investor Presentation

    9 Feb 2026, 7:58PM Supriya Lifescience Limited has informed the Exchange about Investor Presentation

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Change in Directorate

    9 Feb 2026, 7:39PM Details of Appointment and Re-appointment of independent Directors of the Company are enclosed herewith.\r\n\r\nKindly take the same on record.

  • Supriya Lifescience - Change in Director(s)

    9 Feb 2026, 7:38PM Supriya Lifescience Limited has informed the Exchange regarding Change in Director(s) of the company.

  • Supriya Lifescience - Financial Result Quarter Ended On December 31, 2025

    9 Feb 2026, 7:28PM Financial Results for Quarter and Nine Months ended on December 31, 2025.

  • Supriya Lifescience - Outcome of Board Meeting

    9 Feb 2026, 7:26PM Supriya Lifescience Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

  • Supriya Lifescience Q3 net profit up 6.20% at Rs 49.68 cr

    9 Feb 2026, 7:20PM The company reported standalone net profit of Rs 49.68 crore for the quarter ended December 31, 2025 as compared to Rs 46.78 crore in the same period

  • Supriya Lifescience - Board Meeting Outcome for Outcome Of Board Meeting Held On February 09, 2026

    9 Feb 2026, 7:19PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directo

  • Supriya Lifescience - Outcome of Board Meeting

    9 Feb 2026, 7:18PM Supriya Lifescience Limited has informed the Exchange regarding Board meeting held on February 09, 2026.

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Feb 2026, 12:46PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call wil

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Feb 2026, 12:47PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call wil

  • Supriya Lifescience - Reply to Clarification- Financial results

    3 Feb 2026, 12:07PM The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Li

  • Supriya Lifescience - Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results Of The Compa

    2 Feb 2026, 5:38PM Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider

  • Supriya Lifescience has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025

    20 Jan 2026, 3:30PM As of December 2025, 68.30% is owned by Indian Promoters and 31.70% by Public. <p align=justify> Institutional holds 10.19% (Insurance Companies 2.32%

  • Supriya Lifescience - Clarification - Financial Results

    13 Jan 2026, 12:10PM The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Li

  • Supriya Lifescience - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Jan 2026, 4:11PM Supriya Lifescience Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for quarter ended

  • Supriya Lifescience - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    6 Jan 2026, 4:12PM Certificate under Regulation 74 (5) of SEBI (Depositories & Participants) Regulations, 2018 for quarter ended December 31, 20205 is enclosed.

  • Supriya Lifescience - Credit Rating

    30 Dec 2025, 3:40PM Supriya Lifescience Limited has informed the Exchange about Credit Rating

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Credit Rating

    30 Dec 2025, 3:41PM Intimation on Credit Rating to the Company is enclosed.

  • Supriya Lifescience - Trading Window

    28 Dec 2025, 11:34PM Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    26 Nov 2025, 5:25PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 Nov 2025, 5:24PM Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescienc

  • Supriya Life

    29 Sep 2022 , 11:11AM The company gets European drug body's approval for antihistamine drug. Diphenhydramine Hydrochloride is an antihistamine that reduces the effects of natural chemical histamine in the body. It is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms – Positive read through for the stock.

  • Supriya Life gets European drug body's approval for antihistamine drug

    29 Sep 2022 , 9:41AM EDQM grants Certification of Suitability for Diphenhydramine Hydrochloride, API in AntiHistamine therapy
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Supriya Lifescience Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 996.76 815.368 716.083 636.983 335.993
Liabilities 996.76 815.368 716.083 636.983 335.993
Equity 16.097 16.097 16.097 16.097 14.637
Gross Profit 260.796 172.976 128.897 213.984 167.295
Net Profit 187.958 119.114 89.857 151.81 123.593
Cash From Operating Activities 164.675 113.307 66.187 48.801 78.905
NPM(%) 26.98 20.88 19.49 28.64 32.07
Revenue 696.485 570.37 460.938 530.049 385.366
Expenses 435.689 397.394 332.041 316.065 218.071
ROE(%) 17.37 11.01 8.3 14.03 11.42

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
04 Sep 2025 1 50 0 729.7
20 Sep 2024 0.8 40 0 363.1
15 Sep 2023 0.6 30 0 256.65
01 Sep 2022 0.6 30 0 378.15

Peers

Other companies within the same industry or sector that are comparable to Supriya Lifescience Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 725.70 0.24 43.09 386.52 301.39 0.69
Lotus Eye Hospital and Institute Ltd 117.51 -5.00 379.06 1408.43 3.55 0.00
Vaishali Pharma Ltd 7.73 -0.64 0.00 8835.55 3.13 0.00
Astec Lifesciences Ltd 633.05 -0.99 0.00 1328.18 -604.77 0.00

Company Info

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022-Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'.2024-"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". -Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.2025-Supriya Lifescience honoured with Maharashtra State Export Award for two consecutive years-Supriya Lifescience Secures WHO GMP Certification for Ambernath Facility

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022-Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'.2024-"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". -Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.2025-Supriya Lifescience honoured with Maharashtra State Export Award for two consecutive years-Supriya Lifescience Secures WHO GMP Certification for Ambernath Facility

Read More

Parent Organisation

Supriya Lifescience Ltd.

Founded

26/03/2008

Managing Director

Ms.Saloni Satish Wagh

NSE Symbol

SUPRIYAEQ

FAQ

The current price of Supriya Lifescience Ltd is ₹ 677.95.

The 52-week high for Supriya Lifescience Ltd is ₹ 684.30 and the 52-week low is ₹ 673.00.

The market capitalization of Supriya Lifescience Ltd is currently ₹ 5456.33. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Supriya Lifescience Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Supriya Lifescience Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Supriya Lifescience Ltd shares.

The CEO of Supriya Lifescience Ltd is Ms.Saloni Satish Wagh, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT